These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 21597784)

  • 1. Hormonal-therapy in patients with stage-iv breast-cancer at diagnosis.
    Zilembo N; Bajetta E; Noberasco C; Vicario G; Bichisao E; Daprile M
    Oncol Rep; 1995 Jul; 2(4):601-2. PubMed ID: 21597784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer.
    Wiseman LR; Goa KL
    Drugs Aging; 1996 Oct; 9(4):292-306. PubMed ID: 8894526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of formestane in de novo tamoxifen-resistant patients with metastatic breast cancer.
    Noberasco C; Bajetta E; Zilembo N; Di Leo A; Cappuzzo F; Bartoli C; Bono A; Bichisao E
    Oncology; 1995; 52(6):454-7. PubMed ID: 7478430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer.
    Pérez Carrión R; Alberola Candel V; Calabresi F; Michel RT; Santos R; Delozier T; Goss P; Mauriac L; Feuilhade F; Freue M
    Ann Oncol; 1994; 5 Suppl 7():S19-24. PubMed ID: 7873457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formestane: effective therapy in postmenopausal women with advanced breast cancer.
    Bajetta E; Zilembo N; Buzzoni R; Noberasco C; Martinetti A; Ferrari L; Bartoli C; Sacchini V; Attili A; Lepera P
    Ann Oncol; 1994; 5 Suppl 7():S15-7. PubMed ID: 7873456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer.
    Wiseman LR; McTavish D
    Drugs; 1993 Jan; 45(1):66-84. PubMed ID: 7680986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formestane in the treatment of advanced postmenopausal breast cancer.
    Possinger K; Jonat W; Höffken K
    Ann Oncol; 1994; 5 Suppl 7():S7-10. PubMed ID: 7873464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Action and Clinical Relevance of Aromatase Inhibitors.
    Murphy MJ
    Oncologist; 1998; 3(2):129-130. PubMed ID: 10388095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of aromatase complex selective inhibition on insulin-like growth factor 1 and insulin-like growth factor binding protein 3 circulating levels in breast cancer.
    Ferrari L; Bajetta E; Seregni E; Martinetti A; Zilembo N; Noberasco C; Buzzoni R; Botti C; Massaron S; Bichisao E; Celio L; Bombardieri E
    Int J Oncol; 1997 Jul; 11(1):163-7. PubMed ID: 21528196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients.
    Zilembo N; Bajetta E; Bichisao E; Martinetti A; La Torre I; Bidoli P; Longarini R; Portale T; Seregni E; Bombardieri E
    Biomed Pharmacother; 2004 May; 58(4):255-9. PubMed ID: 15183852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coadministration of the aromatase inhibitor formestane and an isopropanolic extract of black cohosh in a rat model of chemically induced mammary carcinoma.
    Nisslein T; Freudenstein J
    Planta Med; 2007 Apr; 73(4):318-22. PubMed ID: 17354167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aromatase inhibitors and breast cancer.
    Brodie AM; Njar VC
    Semin Oncol; 1996 Aug; 23(4 Suppl 9):10-20. PubMed ID: 8824460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risks and benefits of aromatase inhibitors in postmenopausal breast cancer.
    Michaud LB; Buzdar AU
    Drug Saf; 1999 Oct; 21(4):297-309. PubMed ID: 10514021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiestrogen-induced remissions in stage IV breast cancer.
    Manni A; Trujillo J; Marshall JS; Pearson OH
    Cancer Treat Rep; 1976 Oct; 60(10):1445-50. PubMed ID: 1021225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of bone loss in postmenopausal breast cancer patients treated with aromatase inhibitors.
    Cepa M; Vaz C
    Acta Reumatol Port; 2015; 40(4):323-30. PubMed ID: 26922195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer].
    Novoa Vargas A; Font López KC; Amador DD
    Ginecol Obstet Mex; 2011 Sep; 79(9):553-7. PubMed ID: 21966856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study.
    Celio L; Martinetti A; Ferrari L; Buzzoni R; Mariani L; Miceli R; Seregni E; Procopio G; Cassata A; Bombardieri E; Bajetta E
    Anticancer Res; 1999; 19(3B):2261-8. PubMed ID: 10472341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of advanced breast cancer with formestane.
    Murray R; Pitt P
    Ann Oncol; 1994; 5 Suppl 7():S11-3. PubMed ID: 7873455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prediction of hormonal dependency of mammary cancer.
    Block GE; Jensen EV; Polley TZ
    Ann Surg; 1975 Sep; 182(3):342-52. PubMed ID: 169754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.